Acta clinica Croatica, Vol. 40 No. 3, 2001.
Izvorni znanstveni članak
Effect of Octreotide on Growth Hormone Secretion in Patients with Acromegaly
Branka Vizner
Milan Vrkljan
Mladen Sekso
Maja Berković
Josip Rešetić
Miljenko Kalousek
Sažetak
A majority of growth hormone secreting pituitary adenomas respond well to somatostatin and somatostatin analogues. The acute action of octreotide, a synthetic somatostatin analogue, on growth hormone secretion was assessed in 42 patients with clinically and laboratory verified acromegaly. Octreotide was administered subcutaneously in a dose of 50 mg. Blood sampling was performed at 1-hour intervals during 6 hours of testing. The mean basal values of growth hormone (c±SE) was 26.3±4.5 ng/ml (range 6.1-66.6 ng/ml), and of IGF-I 2940±171.7 IU/l (range 2350-4856 IU/l). Reduction in growth hormone values below 5 ng/ml was recorded in 31 (73.8%), suppression by more than 50% in 5 (11.9%) and by more than 45% in 3 (7.1%) patients. Maximal suppression was noticed in the first two hours of testing. In 3 (7.1%) patients, resistance to octreotide with no change in growth hormone values was observed. In conclusion, octreotide reduces growth hormone values in most acromegalic patients. A small proportion of acromegalic patients do not respond well to octreotide, probably due to the lack of somatostatin receptors on tumor cells. We consider the acute octreotide test as a very useful tool in triage of acromegalic patients eligible for medicamentous treatment.
Ključne riječi
Acromegaly, drug therapy; Octreotide, therapeutic use; Octreotide, pharmacology
Hrčak ID:
14865
URI
Datum izdavanja:
3.9.2001.
Posjeta: 2.713 *